Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
*Signup bonus information updated weekly.
HEXO Corp. Common Shares is a drug manufacturers-specialty & generic business based in the US. HEXO CorpCommon Shares shares (HEXO) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||$2.10|
|52-week range||$2.15 - $11.04|
|50-day moving average||$3.26|
|200-day moving average||$5.51|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.43|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-10)||-2.78%|
|1 month (2021-08-17)||-58.00%|
|3 months (2021-06-17)||-63.79%|
|6 months (2021-03-17)||-72.94%|
|1 year (2020-09-17)||176.32%|
|2 years (2019-09-17)||-48.40%|
|3 years (2018-09-17)||6.35|
|5 years (2016-09-13)||N/A|
Valuing HEXO CorpCommon Shares stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of HEXO CorpCommon Shares's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
HEXO CorpCommon Shares's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $190.3 million.
The EBITDA is a measure of a HEXO CorpCommon Shares's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$112.2 million|
|Gross profit TTM||$-57,975,000|
|Return on assets TTM||-7.06%|
|Return on equity TTM||-39.73%|
|Market capitalisation||$598.2 million|
TTM: trailing 12 months
There are currently 21.9 million HEXO CorpCommon Shares shares held short by investors – that's known as HEXO CorpCommon Shares's "short interest". This figure is 48.4% up from 14.7 million last month.
There are a few different ways that this level of interest in shorting HEXO CorpCommon Shares shares can be evaluated.
HEXO CorpCommon Shares's "short interest ratio" (SIR) is the quantity of HEXO CorpCommon Shares shares currently shorted divided by the average quantity of HEXO CorpCommon Shares shares traded daily (recently around 3.8 million). HEXO CorpCommon Shares's SIR currently stands at 5.71. In other words for every 100,000 HEXO CorpCommon Shares shares traded daily on the market, roughly 5710 shares are currently held short.
However HEXO CorpCommon Shares's short interest can also be evaluated against the total number of HEXO CorpCommon Shares shares, or, against the total number of tradable HEXO CorpCommon Shares shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case HEXO CorpCommon Shares's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 HEXO CorpCommon Shares shares in existence, roughly 140 shares are currently held short) or 0.1529% of the tradable shares (for every 100,000 tradable HEXO CorpCommon Shares shares, roughly 153 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against HEXO CorpCommon Shares.
Find out more about how you can short HEXO CorpCommon Shares stock.
We're not expecting HEXO CorpCommon Shares to pay a dividend over the next 12 months.
HEXO CorpCommon Shares's shares were split on a 1:4 basis on 22 December 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your HEXO CorpCommon Shares shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for HEXO CorpCommon Shares shares which in turn could have impacted HEXO CorpCommon Shares's share price.
Over the last 12 months, HEXO CorpCommon Shares's shares have ranged in value from as little as $2.15 up to $11.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while HEXO CorpCommon Shares's is 2.0824. This would suggest that HEXO CorpCommon Shares's shares are significantly more volatile than the average for this exchange and represent a higher risk.
HEXO Corp. , through its subsidiaries, produces, markets, and sells cannabis in Canada. It offers dried cannabis under the Time of Day and H2 lines; Elixir, a cannabis oil sublingual mist product line; and Decarb, an activated fine-milled cannabis powder product. The company offers its adult-use and medical products under the HEXO brand name. Additionally, it offers cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brand; and cannabis products under Original Stash and Up brand names. The company was formerly known as The Hydropothecary Corporation and changes its name to HEXO Corp. in August 2018.
This guide will show you step-by-step instructions on how to buy the Star Atlas DAO (POLIS) token as well as a list of exchanges you can trade it on.
Everything we know about the Sunshine Biopharma IPO, plus information on how to buy in.
Everything we know about the Impossible Foods IPO, plus information on how to buy in.
Everything we know about the TDCX IPO, plus information on how to buy in.
Everything we know about the First Watch Restaurant Group IPO, plus information on how to buy in.
Everything we know about the HeartBeam IPO, plus information on how to buy in.
Everything we know about the Augmedix IPO, plus information on how to buy in.
Everything we know about the Allvue Systems Holdings IPO, plus information on how to buy in.
Everything we know about the Cyngn IPO, plus information on how to buy in.
Everything we know about the Cue Health IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.